🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMy liver enzyme journey — looking for input

My liver enzyme journey — looking for input

Dr.KarenChen Tue, Jul 9, 2024 at 5:54 PM 39 replies 2,351 viewsPage 1 of 8
This thread is more than 23 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Jul 9, 2024 at 5:54 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

The bit I cannot resolve on my own is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
50 20julia.endo, JessicaM_2024, TomFromTexas and 47 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jul 9, 2024 at 6:04 PM#2
Dr.KarenChen said:
The liver data is among the strongest non-weight findings in the class.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

49 19roxy_nash, tony_orlando, Dr.NephBHM_UK and 46 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jul 9, 2024 at 6:14 PM#3
Dr.KarenChen said:
The liver data is among the strongest non-weight findings in the class.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 325 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 11 months: CAP dropped to 228 dB/m (minimal steatosis) and stiffness normalized to 6.1 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

48 18FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 45 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Jul 9, 2024 at 6:24 PM#4
PeptideChemSF said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 325 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible…

Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD). After 11 months on GLP-1 therapy:

MarkerBaselineCurrentNormal Range
ALT62297-56 U/L
AST652510-40 U/L
GGT82339-48 U/L
ALP1127444-147 U/L

FibroScan also improved — liver stiffness from 10.5 kPa to 6.2 kPa. The evidence for GLP-1 agonists in NAFLD/NASH is very promising.

Last edited: Jul 10, 2024 at 12:24 AM
47 17lori_vegas, Dr.PulmRoch, maya_sedona and 44 others
Reply Quote Save Share Report
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
Jul 9, 2024 at 7:15 PM#5
BariatricNurseD said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

This is my experience too, for whatever a second data point is worth.

Last edited: Jul 9, 2024 at 11:15 PM
46 16Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 43 others
Reply Quote Save Share Report
1238

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register